Clinical Drug Experience Knowledgebase

Criteria

Inclusion Criteria:

18-75 years old;
The patient is diagnosed as advanced liver cancer,MUC1/CEA/EpCAM/GPC3 is positive;
There is at least one tumor should be measured,and length≥10mm of focus not at lymph node or length≥10mm of focus at lymph node;
C interval of BCLC;
The patient can't tolerate system(systemic chemotherapy/molecular targeted therapy) or local therapies;
Child-Pugh Score ≤7;
If the patient received adjuvant chemotherapy after local treatment,the time should be more than 4 weeks after the end of chemotherapy, and disease progression or metastasis patients can also assigned into the group;
The time of surgical treatment≥ 3 months ;At the end of the intervention, radiotherapy and the end of the ablation time is more than 4 weeks;
The expected survival time ≥4 months；
The patient did not took any antitumor drugs within two weeks(any antitumor drugs, Chinese patent medicine including Delisheng injection, Kanglaite injection, Aidi injection, huaier granule and Ganfule Pian);
ECOG Score ≤1；
HBV DNA<10^4copies/ml（2000IU/ml);
Serum albumin≥28g/L,ALT and AST≤5.0×ULN,TBIL≤1.5×ULN, electrolyte is normal, proteinuria = 0 ~ 1 +, serum creatinine≤1.5 x ULN;
Tests of blood,liver and kidney should meet the following criteria:WBC≥3×10^9/L,NEUT≥1×10^9/L,Hemoglobin ≥90 g/L,ANC≥1.5×109/L,PLT≥50×10^9/L;
No serious disease are conflicts with the solution(such as autoimmune disease,immunodeficiency,orgen transplantation);
Sign the informed consent;

Exclusion Criteria:

Severe cirrhosis, medium or above ascites;
Cancer embolus in the main portal vein and first branch, Hepatic duct and first branch, hepatic vein, inferior vena cava;;
Patients of T cell lymphoma、myeloma,and patients are using immunosuppressant;
Systemic autoimmune diseases, allergic constitution or immunocompromised patients.
Patients of chronic diseases need immune stimulant or hormone therapy ;
Patients of active bleeding or coagulant function abnormality（PT>16s、APTT>43s、TT>21s、INR≥2）,and patients of bleeding tendency or are receiving thrombolysis and anticoagulation and antiplatelet therapy;
Women who is pregnant or during breast feeding or plan to pregnant in 2 years,and not willing to contraception during the test;
Any significant clinical and laboratory abnormalities, the researchers think that affect the safety, such as: incontrollable active infection (> NCI - CTC AE v4.0 standard level 2), uncontrolled diabetes (> level 2 of NCI - CTC AE v4.0 ), hypertension and can't be controlled by two or less hypotensor(systolic pressure < 140 mmHg, diastolic pressure < 90 mmHg), grade II or above peripheral neuropathy (NCI CTC AE v4.0), grade II or above congestive heart failure (NCI CTC AE v4.0), myocardial infarction in 6 month, thyroid dysfunction (> level 2 of NCI - CTC AE v4.0), etc;
Patients with brain、dura mater metastases or history of psychogeny;
Gastrointestinal bleeding in the past six months or have clear gastrointestinal bleeding tendency,such as: patients of local active ulcerative lesions, defecate occult blood + + above shall not enter into group; defecate occult blood + depend on gastroscopy;
Patients with severe stomach/esophageal varices and need for intervention treatment;
Patients with abdominal fistula, gastrointestinal perforation or abdominal abscess within 4 weeks before the first treatment;
Patients with glomenrular filtration rate abnormal obviously(The endogenous creatinine clearance < 60 ml/min or serum creatinine > 1.5 x ULN);
Positive for HIV antibody;
Patients who are allergic to computed tomography (CT) and magnetic resonance imaging (MRI) contrast agents at the same time, can't imaging assay;
Patients accepted any experimental drugs or pilot medical apparatus and instruments in the past 4 weeks of first treatment;
Other reasons the researchers think not suitable.